Business Context and Reporting Period
Company: SciSparc Ltd.
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date: February 20, 2024
Reporting Period: Month of February 2024
Principal Executive Offices: Tel Aviv, Israel
This filing reports the issuance of a press release regarding the strengthening of the Company's international patent portfolio in collaboration with Clearmind, focusing on next-generation classic psychedelic-based compounds.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a disclosure of a corporate event (press release) rather than a financial statement.
Material Changes
No financial material changes versus the prior comparable period are reported in this document. The material update concerns intellectual property developments rather than financial performance.
Guidance, Outlook, and Management Commentary
- Strategic Development: SciSparc and Clearmind are continuing to strengthen their international patent portfolio.
- Focus Area: Next-generation classic psychedelic-based compounds.
- Regulatory Action: The press release is incorporated by reference into multiple registration statements on Form F-3 and Form S-8.
Investor Verification Checklist
- Verify the specific details of the patent portfolio expansion in the press release furnished as Exhibit 99.1.
- Confirm the status of the collaboration agreement between SciSparc and Clearmind.
- Review the referenced Form F-3 and Form S-8 registration statements for updated prospectus information.
- Check for subsequent filings that may supersede the information contained in this 6-K.